银屑病关节炎患者报告疾病影响的决定因素:14国458例患者中与性别的关联分析
研究基于14国458例确诊银屑病关节炎(PsA)成人患者,评估疾病影响(PsAID)与性别的关联。女性较男性有更差的附着点炎、疼痛、HAQ DI、疲劳和PsAID评分(P<0.001),且更少达到DAPSA和MDA治疗目标。高疾病影响(PsAID≥4)独立关联女性、附着点炎、压痛关节和合并症。
要点
- 女性PsA患者疾病影响、疼痛、疲劳和功能受限均显著高于男性。
- 女性达到DAPSA缓解/低疾病活动度和MDA的比例显著低于男性。
- 高疾病影响独立关联女性、附着点炎、压痛关节和合并症。
核心结论
- 高疾病影响独立关联女性性别、附着点炎、合并症和压痛关节。
- 达到治疗目标时,女性疾病影响仍高于男性。
- 建议将疾病影响纳入PsA达标治疗策略。
研究设计与样本
- ReFlaP研究(NCT03119805)在14个国家连续纳入458例确诊PsA成人患者。
- 采用DAPSA、MDA和PsAID进行评估,用t检验或Wilcoxon检验比较性别间疾病活动度。
- 采用分层广义线性模型分析PsAID与性别的关联。
主要发现
- 女性较男性Leeds附着点炎指数评分更高(0.8±1.7 vs 0.3±0.9,P<0.001)。
- 女性较男性疼痛NRS评分更高(4.7±2.7 vs 3.5±2.7,P<0.001)。
- 女性较男性HAQ DI评分更高(0.9±0.7 vs 0.5±0.6,P<0.001)。
- 女性较男性疲劳NRS评分更高(5.2±3 vs 3.3±2.8,P<0.001)。
- 女性较男性PsAID评分更高(4.1±2.4 vs 2.8±2.3,P<0.001)。
关键数值与推荐
- DAPSA均值女性16.9±14.9,男性12.6±16.6;缓解切点≤4,低疾病活动度>4且≤14。
- MDA达标率女性25.7%,男性50.0%(P<0.001)。
- 高疾病影响(PsAID≥4)关联女性(OR 2.3)、附着点炎(OR 1.34)、压痛关节(OR 1.10)(P<0.001)和合并症(OR 1.22,P=0.002)。
临床怎么用
- 评估PsA时应关注性别差异对疾病影响和达标治疗的影响。
- 对女性患者需更积极管理疼痛、疲劳和附着点炎以改善疾病影响。
- 将PsAID等患者报告结局纳入达标治疗策略。
局限性
- 原文未报告研究设计类型为横断面或队列,无法判断因果关联。
- 原文未报告混杂因素调整细节和模型协变量。
- 原文未报告样本代表性及中心间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sex differences may modify symptoms, disease expression, and treatment effects. The objective of this study was to evaluate the link between life impact and sex in psoriatic arthritis (PsA). METHODS: Remission and Flare in Psoriatic Arthritis (ReFlaP; ClinicalTrials.gov identifier: NCT03119805) was a study in 14 countries of consecutive adult patients with definite PsA. Participants underwent comprehensive PsA assessment using the following measures: Disease Activity in Psoriatic Arthritis (DAPSA), Minimal Disease Activity (MDA), and Psoriatic Arthritis Impact of Disease (PsAID). Disease activity was compared by sex using t-tests or Wilcoxon tests. The association of PsAID with sex was analyzed using hierarchical generalized linear models. RESULTS: Of 458 participants, 50.2% were male and the mean ± SD age was 53.1 ± 12.6 years. The mean ± SD PsA duration was 11 ± 8.2 years, and 51.5% of participants were being treated with biologic disease-modifying antirheumatic drugs. Women, compared to men, had worse mean ± SD Leeds Enthesitis Index scores (0.8 ± 1.7 versus 0.3 ± 0.9), pain on a numerical rating scale (NRS; range 0-10) (4.7 ± 2.7 versus 3.5 ± 2.7), HAQ DI scores (0.9 ± 0.7 versus 0.5 ± 0.6), fatigue on an NRS (5.2 ± 3 versus 3.3 ± 2.8), and PsAID scores (4.1 ± 2.4 versus 2.8 ± 2.3) (P < 0.001 for all). Women were also less frequently at treatment target compared to men according to DAPSA (cutoffs of ≤4 for remission and >4 and ≤14 for low disease activity; mean ± SD score 16.9 ± 14.9 in women versus 12.6 ± 16.6 in men) and MDA (25.7% versus 50.0%; P < 0.001 for all) scores. High life impact (PsAID score ≥4) was associated with female sex (odds ratio [OR] 2.3), enthesitis (OR 1.34), tender joints (OR 1.10)(P < 0.001 for all), and comorbidities (OR 1.22, P = 0.002). CONCLUSION: High life impact was independently associated with female sex, enthesitis, comorbidities, and tender joints. At treatment target, women had higher life impact compared to men. It is necessary for life impact to become a part of PsA treat-to-target strategies.
引用
- Orbai AM, Perin J, Gorlier C, et al. Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. Arthritis Care Res (Hoboken). 2020. PMID: 31609525. doi:10.1002/acr.24090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。